Xiaohu Deng
Chief Tech/Sci/R&D Officer at Vividion Therapeutics, Inc.
Profile
Xiaohu Deng is currently the Head-Technical Operations at Vividion Therapeutics, Inc. Prior to this, he worked as the Senior Director & Head-CMC at Kura Oncology, Inc. and as the Senior Vice President-Product Development at Viracta Therapeutics, Inc. Deng holds a doctorate degree from Emory University and undergraduate and graduate degrees from Fudan University.
Xiaohu Deng active positions
| Companies | Position | Start |
|---|---|---|
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Former positions of Xiaohu Deng
| Companies | Position | End |
|---|---|---|
| KURA ONCOLOGY, INC. | Corporate Officer/Principal | - |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Training of Xiaohu Deng
| Emory University | Doctorate Degree |
| Fudan University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| KURA ONCOLOGY, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
- Stock Market
- Insiders
- Xiaohu Deng